Conference Coverage

Tanezumab acts fast for OA pain relief

TORONTO – The nerve growth factor inhibitor separated from placebo in the first 3-5 days in a phase 3 randomized, controlled trial.

Conference Coverage

Patients rate burden of OA equal to RA

TORONTO – “The severity of disease burden in OA to the patient appears to be underrated by the medical community, general public, and even...